TG THERAPEUTICS, INC.

TGTX · Nasdaq · SIC 2834: Pharmaceutical Preparations
373
SEC Filings

Business Summary

TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its lead approved product is BRIUMVI (ublituximab-xiiy) 150 mg/6 mL Injection for intravenous therapy, indicated for relapsing forms of multiple sclerosis (RMS) in the United States. The company also has additional product candidates in clinical development and relies on third-party manufacturers and licensors for its pipeline.

Next Earnings

Q2 FY2026 — expected 2026-08-13

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionTGTXdiscussed_in_filing Artificial Intelligence
topic_mentionTGTXdiscussed_in_filing Cybersecurity
topic_mentionTGTXdiscussed_in_filing Trusted Computing
topic_mentionTGTXdiscussed_in_filing Blockchain & Crypto
topic_mentionTGTXdiscussed_in_filing Regulation
topic_mentionTGTXdiscussed_in_filing Healthcare & Bio
topic_mentionTGTXdiscussed_in_filing Platform & Ecosystem
topic_mentionTGTXdiscussed_in_filing Sovereign & Government
topic_mentionTGTXdiscussed_in_filing Artificial Intelligence
topic_mentionTGTXdiscussed_in_filing Cybersecurity
topic_mentionTGTXdiscussed_in_filing Trusted Computing
topic_mentionTGTXdiscussed_in_filing Blockchain & Crypto
topic_mentionTGTXdiscussed_in_filing Regulation
topic_mentionTGTXdiscussed_in_filing Healthcare & Bio
topic_mentionTGTXdiscussed_in_filing Platform & Ecosystem
topic_mentionTGTXdiscussed_in_filing Sovereign & Government
topic_mentionTGTXdiscussed_in_filing Artificial Intelligence
topic_mentionTGTXdiscussed_in_filing Cybersecurity
topic_mentionTGTXdiscussed_in_filing Trusted Computing
topic_mentionTGTXdiscussed_in_filing Blockchain & Crypto

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-272025-12-310001437749-26-006133EDGAR93K words
2025-03-032024-12-310001437749-25-005908EDGAR—
2024-02-292023-12-310001437749-24-006144EDGAR—
2023-03-012022-12-310001558370-23-002610EDGAR—
2022-03-012021-12-310001558370-22-002617EDGAR—
2021-03-012020-12-310001558370-21-002149EDGAR—
2020-03-022019-12-310001558370-20-001897EDGAR—
2019-03-012018-12-310001654954-19-002189EDGAR—
2018-03-152017-12-310001654954-18-002638EDGAR—
2017-03-162016-12-310001654954-17-002050EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-052025-09-300001437749-25-033363EDGAR67K words
2025-08-082025-06-300001437749-25-025745EDGAR—
2025-05-092025-03-310001437749-25-015804EDGAR—
2024-11-072024-09-300001437749-24-033948EDGAR—
2024-08-092024-06-300001437749-24-025853EDGAR—
2024-05-062024-03-310001437749-24-014849EDGAR—
2023-11-062023-09-300001437749-23-030412EDGAR—
2023-08-042023-06-300001558370-23-013429EDGAR—
2023-05-082023-03-310001558370-23-008385EDGAR—
2022-11-092022-09-300001558370-22-017180EDGAR—
2022-08-092022-06-300001558370-22-012854EDGAR—
2022-05-102022-03-310001558370-22-008130EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-200001437749-26-009253EDGAR1K words
2026-02-260001437749-26-005733EDGAR—
2026-01-130001437749-26-001194EDGAR—
2025-11-030001437749-25-032658EDGAR—
2025-08-040001437749-25-024480EDGAR—
2025-06-130001437749-25-020335EDGAR—
2025-05-050001437749-25-014402EDGAR—
2025-03-030001437749-25-005802EDGAR—
2025-01-140001437749-25-001106EDGAR—
2024-11-040001437749-24-033055EDGAR—

373 total filings indexed. 341 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Tags

relapsing-forms-of-multiple-sclerosis-(rms) b-cell-diseases neurology oncology/hematology

Company Identity

CIK0001001316
TickerTGTX
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 431afa6636914709d1c8bcd81c077f78a96224b1bbfc6e3329a8c52710922698
parent: 70e9f3e4d00bd5e2bd91b6723a1b95d1424a67e2548cba79432da90059d3209f
content hash: ebc145a9ef04a0b852d7a272b526723c9f79a3dfe90476707fe0a8f244dfff5a
signed: 2026-04-13T04:47:47.253Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf